Segall Bryant & Hamill LLC Acquires 27,128 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Segall Bryant & Hamill LLC grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 51.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 79,518 shares of the biopharmaceutical company’s stock after acquiring an additional 27,128 shares during the period. Segall Bryant & Hamill LLC owned about 0.05% of TG Therapeutics worth $2,393,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Blue Trust Inc. lifted its holdings in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,737 shares during the period. Synergy Asset Management LLC bought a new stake in TG Therapeutics in the fourth quarter valued at approximately $75,000. Finally, GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,171 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 1.4 %

NASDAQ:TGTX opened at $40.20 on Friday. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $6.31 billion, a price-to-earnings ratio of -401.96 and a beta of 2.30. The firm has a fifty day simple moving average of $34.17 and a two-hundred day simple moving average of $30.18.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on TGTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.